143 related articles for article (PubMed ID: 28763839)
1. [Expression of ATAD2 in different liver lesions and its clinical significance].
Liu F; Zhou X; Ji HH; Li H; Xiang FG
Zhonghua Gan Zang Bing Za Zhi; 2017 May; 25(5):339-343. PubMed ID: 28763839
[No Abstract] [Full Text] [Related]
2. ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection.
Hwang HW; Ha SY; Bang H; Park CK
Cancer Res Treat; 2015 Oct; 47(4):853-61. PubMed ID: 25687855
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma.
Ekin U; Yuzugullu H; Ozen C; Korhan P; Bagirsakci E; Yilmaz F; Yuzugullu OG; Uzuner H; Alotaibi H; Kirmizibayrak PB; Atabey N; Karakülah G; Ozturk M
J Gastrointest Cancer; 2021 Dec; 52(4):1356-1369. PubMed ID: 34738187
[TBL] [Abstract][Full Text] [Related]
4. Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma.
Meng X; Wang L; Zhu B; Zhang J; Guo S; Li Q; Zhang T; Zheng Z; Wu G; Zhao Y
Biomed Res Int; 2020; 2020():8657468. PubMed ID: 32462022
[TBL] [Abstract][Full Text] [Related]
5. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
[TBL] [Abstract][Full Text] [Related]
6. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE
Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450
[TBL] [Abstract][Full Text] [Related]
7. Liver cell dysplasia in liver cirrhosis and hepatocellular carcinoma.
Szczepański W
Pol J Pathol; 1997; 48(3):147-57. PubMed ID: 9401407
[TBL] [Abstract][Full Text] [Related]
8. Expression of transforming growth factor-alpha and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance.
Zhang J; Wang WL; Li Q; Qiao Q
World J Gastroenterol; 2004 Mar; 10(6):830-3. PubMed ID: 15040026
[TBL] [Abstract][Full Text] [Related]
9. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
10. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.
Liu T; Yao M; Liu S; Wang L; Wang L; Hou J; Ma X; Jia J; Zhao J; Zhuang H; Lu F
Oncotarget; 2017 Mar; 8(10):16498-16506. PubMed ID: 28157705
[TBL] [Abstract][Full Text] [Related]
11. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma.
Rashad NM; El-Shal AS; Shalaby SM; Mohamed SY
Mol Cell Biochem; 2018 Oct; 447(1-2):125-136. PubMed ID: 29455432
[TBL] [Abstract][Full Text] [Related]
12. [Correlation of triggering receptors expressed on myeloid cells-1 with the oncogenesis and progression of hepatocellular carcinoma].
Li W; Zhang N; Ou Y; Zhou Z; Zhao F; Wu Q; Yang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Dec; 35(12):1705-9, 1720. PubMed ID: 26714901
[TBL] [Abstract][Full Text] [Related]
13. Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC.
Trerotoli P; Fransvea E; Angelotti U; Antonaci G; Lupo L; Mazzocca A; Mangia A; Antonaci S; Giannelli G
Mol Cancer; 2009 May; 8():29. PubMed ID: 19473531
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of somatostatin receptor expression in human hepatocellular carcinoma tissue to serum alpha-fetoprotein concentration].
Xie YM; Yan LN; Wei B; Guo MM; Tang CW
Ai Zheng; 2007 Jul; 26(7):688-92. PubMed ID: 17626741
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of pi class glutathione S-transferase and alpha-fetoprotein in hepatocellular carcinoma and chronic liver disease.
Yusof YA; Yan KL; Hussain SN
Anal Quant Cytol Histol; 2003 Dec; 25(6):332-8. PubMed ID: 14714299
[TBL] [Abstract][Full Text] [Related]
16. Expression of P53 and HSP70 in Chronic Hepatitis, Liver Cirrhosis, and Early and Advanced Hepatocellular Carcinoma Tissues and Their Diagnostic Value in Hepatocellular Carcinoma: An Immunohistochemical Study.
Wang Z; Gou W; Liu M; Sang W; Chu H; Zhang W
Med Sci Monit; 2015 Oct; 21():3209-15. PubMed ID: 26494212
[TBL] [Abstract][Full Text] [Related]
17. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
[TBL] [Abstract][Full Text] [Related]
18. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
19. ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.
Liu Q; Liu H; Li L; Dong X; Ru X; Fan X; Wen T; Liu J
Int J Oncol; 2020 Jan; 56(1):219-231. PubMed ID: 31746426
[TBL] [Abstract][Full Text] [Related]
20. A Panel of Genes Identified as Targets for 8q24.13-24.3 Gain Contributing to Unfavorable Overall Survival in Patients with Hepatocellular Carcinoma.
Zhao K; Zhao Y; Zhu JY; Dong H; Cong WM; Yu Y; Wang H; Zhu ZZ; Xu Q
Curr Med Sci; 2018 Aug; 38(4):590-596. PubMed ID: 30128866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]